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Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wetter-
gren A, Svendsen LB, Meisner S, Hovendal C, Vilsbøll T, Knop
FK, Holst JJ. The effect of exogenous GLP-1 on food intake is lost
in male truncally vagotomized subjects with pyloroplasty. Am J
Physiol Gastrointest Liver Physiol 304: G1117–G1127, 2013. First
published April 18, 2013; doi:10.1152/ajpgi.00035.2013.—Rapid
degradation of glucagon-like peptide-1 (GLP-1) by dipeptidyl pepti-
dase-4 suggests that endogenous GLP-1 may act locally before being
degraded. Signaling via the vagus nerve was investigated in 20
truncally vagotomized subjects with pyloroplasty and 10 matched healthy
controls. Subjects received GLP-1 (7-36 amide) or saline infusions during
and after a standardized liquid mixed meal and a subsequent ad libitum
meal. Despite no effect on appetite sensations, GLP-1 significantly
reduced ad libitum food intake in the control group but had no effect in
the vagotomized group. Gastric emptying was accelerated in vagoto-
mized subjects and was decreased by GLP-1 in controls but not in
vagotomized subjects. Postprandial glucose levels were reduced by the
same percentage by GLP-1 in both groups. Peak postprandial GLP-1
levels were approximately fivefold higher in the vagotomized subjects.
Insulin secretion was unaffected by exogenous GLP-1 in vagotomized
subjects but was suppressed in controls. GLP-1 significantly reduced
glucagon secretion in both groups, but levels were approximately twofold
higher and were nonsuppressible in the early phase of the meal in
vagotomized subjects. Our results demonstrate that vagotomy with py-
loroplasty impairs the effects of exogenous GLP-1 on food intake, gastric
emptying, and insulin and glucagon secretion, suggesting that intact vagal
innervation may be important for GLP-1’s actions.
GLP-1; degradation; DPP-4; vagus nerve; vagotomy; meal test; insu-
lin and glucagon secretion
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) is an intestinal hormone, re-
leased into the circulation from endocrine L cells in the small
intestine during meal ingestion (31). Moreover, GLP-1 is pro-
duced in neurons in the nucleus of the solitary tract. GLP-1
receptors (GLP-1Rs) are widely expressed both in the brain,
particularly in areas involved in control of food intake including
the arcuate and paraventricular nuclei of the hypothalamus (42),
and in the periphery, where they are found in the gastrointestinal
tract, pancreatic islets, portal vein, liver, and vagus nerve [re-
viewed by Holst (30)]. The effects of the hormone include
augmentation of glucose-stimulated insulin secretion (incretin
effect) (50), inhibition of glucagon secretion (50), delay of gastric
emptying (enterogastrone function) (69), and suppression of ap-
petite and food intake (19). Thus GLP-1 administration is asso-
ciated with reduction of both appetite and subsequent food intake
(10, 31) in healthy as well as in obese and diabetic subjects (19,
24, 49). Furthermore, gastric emptying is inhibited (13, 19, 47),
limiting propulsion of additional food, which, together with the
effects of GLP-1 on the endocrine pancreas (23, 68), results in
beneficial conditions for the deposition of already-absorbed nu-
trients in the liver and periphery. However, the exact mechanisms
behind these effects remain to be elucidated. The rapid dipeptidyl
peptidase-4 (DPP-4)-mediated degradation and inactivation of
GLP-1 (11, 27, 41), suggests that endogenous GLP-1 may act
locally, possibly via the vagus nerve, before being degraded.
Several findings support the hypothesis of vagal afferent sensing
of GLP-1: 1) the GLP-1R gene is expressed in large amounts in
the nodose ganglion (44), 2) vagal nerve terminals innervating the
portal vein were reported to express GLP-1R (67), and 3) both
intraportal and intravenous GLP-1 infusions in rats lead to in-
creased impulse generation in vagal afferent fibers (8, 48). Even
though GLP-1Rs have not yet been identified on neurons inner-
vating the intestine, it seems plausible that they may be present on
vagal terminals throughout the gastrointestinal tract, considering
the extensive GLP-1R gene expression in the nodose ganglion
(44). Thus it has been shown in rats that subdiaphragmatic
deafferentation prevents anorexia (59) induced by intraperitoneal
GLP-1, and ganglionic blockade eliminated the insulinotropic
effects of intraportally infused GLP-1 (5). It therefore seems likely
that GLP-1 acts locally, possibly via the vagus nerve, prior to
degradation.
The present study was designed to evaluate the importance
of vagal pathways for the effect of GLP-1 on food intake
(primary end point), appetite sensations, and gastric emptying,
and, additionally, on meal-related plasma glucose (PG), insu-
lin, and glucagon responses. Subjects with truncal vagotomy
and pyloroplasty were evaluated during two double meal tests,
with and without GLP-1 infusion, and compared with matched
healthy subjects with intact vagal innervation.
MATERIALS AND METHODS
Study Protocol
The study was approved by the Scientific-Ethical Committee of the
Capital Region of Denmark (registration no. H-D-2008-050) and by the
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Danish Data Protection Agency (journal no. 2008-41-2220). It was registered
at www.clinicaltrials.gov (ClinicalTrials.gov ID: NCT01176890) and per-
formed in accordance with the Helsinki declaration II. Written and oral
informed consent was obtained from all participants.
Subjects
Eleven subjects who had undergone surgery in the period 1964–
1977 (truncal vagotomy and pyloroplasty ad modum Heineke-Miku-
lic) for uncomplicated duodenal ulcer were screened. During the
screening visit, all underwent a physical examination and blood
samples were drawn for measurements of standard hematological and
clinical biochemistry parameters. Albumin-to-creatinine ratio was
measured in urine samples. Exclusion criteria were diabetes mellitus,
overweight [body mass index (BMI) above 30 kg/m2], inflammatory
bowel disease, gut resection (except appendectomy), kidney or liver
disease (creatinine 150 M and/or albuminuria; plasma alanine
aminotransferase or plasma aspartate aminotransferase above two
times normal values) and medication that could not be paused for 12
h. One patient with severe dumping symptoms was excluded. Two
patients with recurrent gastric ulcer (one after NSAID treatment) and
one with Type 2 diabetes, who was well regulated with only 0.5 mg
of glimepiride once daily [fasting PG 5.5 mM and glycated hemoglo-
bin A1c (HbA1c) of 4.9%] were included; all calculations and
statistical analyses were carried out both with and without exclusion
of these three participants and the results were identical. Furthermore,
10 subjects treated in the period 2004–2008 with cardia resection ad
modum Ivor Lewis, including truncal vagotomy and pyloroplasty, for
esophageal cancer were screened and included. None of these subjects
showed any sign of tumor recurrence. HbA1c (%) was slightly lower
in patients treated for duodenal ulcer than esophagus cancer, which
otherwise showed no differences. Furthermore, the results from this
study were similar in the two groups and were therefore analyzed
together. All the subjects operated for esophageal cancer had received
chemo and radiation therapy postoperatively and were treated with
proton pump inhibitors (for prevention of gastroesophageal reflux).
Additional medications included (whole vagotomized group): statins
(dyslipidemia, N  3), anticoagulant therapy (dipyramidol or acetyl-
salicylic acid, N 3), antihypertensive therapy [thiazides, angiotensin
converting enzyme (ACE) inhibitors, calcium antagonists, and/or
beta-blockers, N  3], antithyroid and thyroid hormone substitution
(thycapzol and eltroxin, N  1), or therapy for benign prostate
hypertrophy (alpha-blocker, N  1). The vagotomy of those treated
for duodenal ulcer was at that time considered complete as evidenced
by more than 90% reduction in insulin-induced peak acid output 3 mo
and 5 yr after the operation (confirmed from existing hospital records
for five of the participants in this study). No similar test was per-
formed in the subjects operated for esophageal cancer with cardia
resection. However, their type of operation (cardia resection ad
modum Ivor Lewis) did involve a truncal vagotomy due to the
anatomical proximity of the cancer to the vagal nerve and therefore
also included a pyloroplasty (54).
Ten healthy subjects matched to the vagotomized subjects with
regard to age, sex, and BMI, all without family history of diabetes,
were included and served as controls. Medications in this group
included antihypertensive treatment (ACE inhibitors, calcium antag-
onists, and/or thiazides, N  3), anticoagulant therapy (acetylsalicylic
acid, N  2), or therapy for benign prostate hypertrophy (alpha-
blocker, N  1).
The truncally vagotomized subjects treated for duodenal ulcer were
located by use of old hospital records from throughout Denmark. The
truncally vagotomized subjects treated with cardia resection were all
treated in the Rigshospital, Copenhagen, Denmark and were identified
from the local archive. The healthy control subjects were recruited
from lists of subjects who had previously participated in studies and
who had given their consent to be contacted again, or from advertising
in newspapers or on the internet. Subjects received a letter and a
phone call with a request to participate.
All medications were paused at least 12 h prior to examinations.
Subject characteristics are shown in Table 1; all participants had
normal clinical and biochemical parameters.
Experimental Procedures
Subjects were studied on three occasions including a “sham-
feeding” test and two meal tests. On each occasion subjects were
studied after a 12-h fast (including abstinence from smoking and
drinking) and were instructed to maintain an unchanged lifestyle but
to abstain from alcohol and exercise in the 24 h leading up to the
experiments and to standardize their food intake on the day before
each experiment. Subjects were seated during all experiments. During
the sham feeding, one cannula was inserted into an antecubital vein in
one arm for collection of arterialized blood samples [cannulated
forearm placed in a heating box (50°C) throughout the experiments].
During the meal test, an additional cannula was inserted into the
contralateral antecubital vein for GLP-1 or saline infusion.
To evaluate vagal integrity, participants underwent a 15-min chew-
and-spit sham feeding (4), with a test meal consisting of a standard-
ized breakfast platter (including eggs, bacon, bread, butter, cheese,
marmalade, yogurt, fruits, pancakes, orange juice, and tea or coffee).
Participants were observed throughout the sham feeding and were
instructed to avoid swallowing any food, drink, or saliva. Blood was
drawn at 15, 0, 15, 30, 45, and 60 min. For bedside PG measure-
ment, blood was collected into fluoride tubes and centrifuged imme-
diately (7,400 g for 1 min at room temperature). For analyses of total
GLP-1 and pancreatic polypeptide (PP) blood was distributed into
chilled tubes containing EDTA.
Thereafter, subjects were investigated on two different occasions
during infusion of GLP-1 [1.2 pmol·kg1·min1; the original, thera-
peutic dose of GLP-1 (46)] or saline in a randomized, placebo-
controlled single-blinded crossover design. At time 0 min, a continu-
ous intravenous infusion of GLP-1 or saline was started and continued
throughout the experiment. After 30 min, a standardized liquid mixed
meal was served and consumed over 10 min, with participants being
encouraged to drink at an even rate during the 10 min. After 240 min,
a warm lunch was served with 300 ml chilled water, and subjects were
instructed to eat ad libitum until comfortably satisfied. The weight of
food consumed was measured. Appetite, well-being, and palatability
ratings for the ad libitum meal were made by visual analog scales
(VASs). Arterialized blood was drawn 15, 10, and 0 min before and
15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 min after the
meal. For bedside PG measurement, blood was collected into fluoride
tubes and centrifuged immediately (7,400 g for 1 min at room
temperature). Blood was distributed into chilled tubes containing a
Table 1. Subject characteristics
Vagotomized Controls P
Sex, M/F 20/0 10/0
Age, yr 68 (5) 67 (3) 0.5666
BMI, kg/m2 24 (3) 25 (2) 0.2690
Waist:hip ratio 0.9 (0.1) 0.9 (0.1) 0.4334
Systolic blood pressure, mmHg 146 (20) 142 (15) 0.6403
Diastolic blood pressure, mmHg 85 (12) 90 (9) 0.1868
Fasting PG, mM 5.5 (0.7) 5.4 (0.5) 0.7451
HbA1c, % 5.7 (0.4) 5.5 (0.5) 0.0211
HOMA2-IR 1.5 (1.6) 0.9 (0.5) 0.3101
HOMA2-%B 83 (43) 81 (8.7) 0.2664
HOMA2-%S 120 (93) 161 (135) 0.6782
Data are mean values with SD in parentheses. BMI, body mass index; PG,
plasma glucose; HbA1c, glycated hemoglobin A1c; HOMA, homeostasis
model assessment; IR, insulin resistance; %B, beta cell function; %S, insulin
sensitivity.
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DPP-4 inhibitor (valine pyrrolidide, 0.01 mM final concentration, a
gift from Novo Nordisk, Bagsværd, Denmark) and EDTA plus apro-
tinin (500 kIU/ml blood; Trasylol; Bayer, Leverkusen, Germany) for
analyses of glucagon, GLP-1, and PP. Blood was collected in dry
tubes (left 20 min at room temperature for coagulation) for insulin and
C-peptide analyses and into lithium-heparin tubes for acetaminophen
measurements. Blood was centrifuged (for 20 min at 1,200 g and 4°C)
and plasma for GLP-1, glucagon, and acetaminophen analyses was
stored at 20°C, and serum for insulin and C-peptide analyses was
stored at 80°C.
The standardized liquid mixed meal consisted of 100 g NAN1
[2,170 kJ: 10% protein (2.8% casein and 6.7% whey), 58% lactose,
and 28% fat (11.3% saturated, 10% monounsaturated, and 4.7%
polyunsaturated); Nestlé Nutrition, Amsterdam, The Netherlands]
dissolved in 300 ml water; 1.5 g acetaminophen (Panodil, GlaxoSmith-
Kline, Copenhagen, Denmark) was added to the meal. Acetaminophen is
poorly absorbed from the stomach but rapidly so from the proximal part
of the small intestine. Its absorption rate can, therefore, be used as an
indirect measurement of gastric emptying (71).
The ad libitum meal consisted of an appetizing but rather homog-
enous mixture of minced meat, pasta, corn, carrots, and green pepper
(37% fat, 13% protein, and 50% carbohydrates) as used in previous
studies (3, 19, 21). The participants were not allowed to select certain
food items from the ad libitum meal. The amount of food presented
and remaining after the ad libitum meal was measured by use of a
digital scale. Subjects had 30 min to eat until they were comfortably
satisfied.
Appetite, well-being, and palatability for the ad libitum meal
ratings were made using 10 cm-VASs with words anchored at each
end expressing the most positive and the most negative rating. VAS
was used to assess satiety, hunger, fullness, prospective food con-
sumption, well-being, nausea, and thirst every 30 min, starting at 0
min, and for measurement of palatability of the ad libitum meal
(visual appeal, taste, smell, aftertaste, and overall palatability) imme-
diately after consumption of the ad libitum meal. On the VAS 10 cm
equals “I cannot eat another bite” (satiety), “I have never been more
hungry” (hunger), “I am totally full” (fullness), “I can eat a lot”
(prospective food consumption), “I feel really good” (well-being), “I
have never been more nauseated” (nausea), “I have never been more
thirsty” (thirst), “The meal looks really good” (visual appeal), “The
meal smells wonderful” (smell), “The taste of the meal is wonderful”
(taste), “The meal has a strong aftertaste” (aftertaste), and “The meal
is appetizing” (overall palatability). VAS ratings for appetite sensation
have been validated previously in a study involving young healthy
male subjects (20), not in an elderly age group, as studied here.
However, VAS ratings for appetite sensation have been used previ-
ously in elderly age group (22). We therefore regard VAS ratings
applicable for appetite estimations also in our groups. Notably, the
groups in this study were matched for age.
GLP-1 Infusions
Synthetic GLP-1(7-36 amide) (PolyPeptide Laboratories, Wolfen-
büttel, Germany) (correctness of structure and purity was assessed by
mass, sequence, and HPLC analysis) was dissolved in sterilized water
containing 2% human albumin (Statens Serum Institut, Copenhagen,
Denmark), thereafter subjected to sterile filtration, and dispensed into
vials and stored frozen under sterile conditions until the experiment.
Laboratory Analyses
PG was determined by the glucose oxidase method, using a glucose
analyzer (Yellow Springs Instrument model 2300 STAT plus ana-
lyzer; YSI, Yellow Springs, OH). All plasma samples for analysis of
PP, GLP-1, and glucagon were extracted with ethanol (70% final
concentration) before analysis. PP was analyzed by using the midre-
gion-specific antibody, code no. HYB 347-07 (Statens Serum Institut,
Copenhagen, Denmark), with human PP standards and 125I-labeled
human PP (cat. no. NEX315, Perkin Elmer, Boston, MA) (15). GLP-1
levels, expressed as total GLP-1, were measured by use of using
antiserum 89390, which requires the intact amidated COOH-terminus
of the molecule (52). Glucagon levels were assayed by use of the
COOH-terminally directed antiserum 4305, which measures glucagon
of pancreatic origin (55). Serum insulin and C-peptide concentrations
were quantified by routine immunoassays (Siemens Healthcare Diag-
nostics, Ballerup, Denmark) for the ADVIA Centaur XP analyzer and
plasma acetaminophen by a routine enzymatic colorimetric assay
(Ortho-Clinical Diagnostics, Johnson & Johnson, Birkerød, Denmark)
for the Vitros 5.1. FS analyzer (39, 43).
Calculations and Statistical Analyses
All statistical analyses were carried out with GraphPad Prism
version 5.00 for Windows (GraphPad Software, San Diego, CA).
Results are reported as mean values with standard deviations in
parentheses. A two-sided P value 0.05 was considered significant.
Data were tested for normal distribution by D’Agostino-Pearson
omnibus K2 normality test. Two-way repeated-measures analysis of
variance (ANOVA), followed by Bonferroni posttests, were applied to
test for differences in repeatedly measured values between days
(absolute PG, hormone concentrations, acetaminophen, and VAS).
Paired t-tests within the groups and unpaired t-tests between groups
were used for comparisons between single values [between baseline,
food intake and area under the curve (AUC) values] in data that
followed a normal distribution. For data that did not follow a normal
distribution, the significance of difference was tested using the Wil-
coxon test for paired difference and the Mann-Whitney test for
unpaired difference. Insulin resistance, as well as steady-state beta cell
function and insulin sensitivity, the latter expressed in percent of a
normal reference population, were calculated using the homeostatic
model assessment (The HOMA2 calculator: http://www.dtu.ox.ac.uk/
index.php?maindoc/homa/). AUC and incremental AUC (iAUC;
i.e., baseline levels subtracted) were calculated by use of the trape-
zoidal rule. A mean appetite score was calculated (based on VAS
ratings) by the formula {[hunger  prospective intake  (100 
satiety)  (100  fullness)]/4} (64).
RESULTS
Sham Feeding
Only 19 vagotomized subjects and 9 control subjects partic-
ipated in the sham feeding. The vagotomized subject not
participating in the sham feeding had a documented negative
insulin test at both 3 mo and 5 yr after the operation. Baseline
values of PP were identical in the vagotomized subjects and
control subjects [23(23) vs. 21(15) pM, P  0.8258; Fig. 1A].
PP levels increased in 12 of the 19 (63%) vagotomized subjects
and 8 of the 9 (89%) control subjects during the 1 h after the
sham feeding. Examination of the cephalic responses during
the first 15 min after sham feeding revealed an absence of
vagally stimulated PP secretion in the vagotomized subjects
compared with the control subjects [increase of PP secretion in
percent after sham feeding: 8(56) vs. 64(55)%, P  0.0195],
(Fig. 1B). Mean baseline PG values were similar in the vagot-
omized subjects and control subjects [5.4(0.5) vs. 5.1(0.4) pM,
P  0.1230], and a small rise in PG following sham feeding
(P  0.05) was observed in both groups (Fig. 1C). Baseline
GLP-1 levels were similar in vagotomized subjects and control
subjects [11.5(6.1) vs. 8.9(2.6) pM, P  0.2533] and were
unaltered during sham feeding in both groups (Fig. 1D).
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Ad Libitum Meal Including Palatability Rating
GLP-1 reduced ad libitum food intake in controls but had no
effect in the vagotomized group [control subjects: 367(115)
(saline) vs. 318(92) (GLP-1) g, P  0.0417; vagotomized
subjects: 286(95) (saline) vs. 268(116) (GLP-1) g, P 0.2049].
There was no significant difference in food intake between the
two groups on any of the experimental days (Fig. 2). The palat-
ability ratings were identical during saline and GLP-1 infusions
in both groups (Table 2). Vagotomized subjects rated the visual
appeal and smell of the ad libitum meal higher than the control
subjects both during saline and GLP-1 infusions and overall
palatability higher only during GLP-1 infusions. Otherwise
there was no difference between the groups.
Standardized Liquid Mixed Meal Test
Appetite and well-being sensations. There was no difference
between the groups in baseline values of any of the VAS scores,
except for a slightly higher well-being score on the day with
GLP-1 infusion in the vagotomized subjects. After the liquid
meal, decreased ratings of appetite score and increased ratings of
satiety and fullness were seen on both days (Fig. 3) in both groups.
Furthermore, vagotomized subjects reported decreased ratings of
hunger, prospective food consumption, and thirst after the liquid
meal. Control subjects reported a higher rating of appetite score
and prospective food consumption than the vagotomized subjects.
In contrast, the vagotomized subjects reported a higher rating of
satiety and fullness than the controls, but there were no differences
between the groups in hunger ratings (Table 3). No differences
were seen in any of the VAS ratings when comparing saline and
GLP-1 infusions. About 60–75 min after the liquid meal, two of
the vagotomized subjects experienced nausea, dizziness, and fa-
tigue and had to lie down for about 15–20 min before returning to
their habitual state. Ten had to use the restroom one to two times
(loose stools) between 1 and 2 h after the liquid meal. These side
effects of the standardized liquid mixed meal were equally dis-
tributed between the vagotomized subjects treated for duodenal
ulcer and esophagus cancer. The symptoms were the same on both
experimental days and the subjects were familiar with these
symptoms. Despite this, there was no difference in VAS for either
nausea or well-being between the vagotomized subjects and
control subjects.
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Fig. 1. A: time course of changes in plasma pancreatic polypeptide (PP) before and after sham feeding in vagotomized subjects () and control subjects ().
B: changes in plasma PP immediately after sham feeding in vagotomized subjects (black bar) and control subjects (white bar). C: plasma glucose before and after
sham feeding in vagotomized subjects () and control subjects (). D: total glucagon-like peptide-1 (GLP-1) plasma concentrations before and after sham feeding
in vagotomized subjects () and control subjects (). Sham feeding was started at 0 min and lasted 15 min. Data represent mean values and standard deviations
from 19 vagotomized subjects with pyloroplasty and 9 control subjects. *Significantly reduced PP secretion in the first 15 min after sham feeding in the
vagotomized subjects (P  0.0195).
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Acetaminophen. As illustrated in Fig. 4A, gastric emptying
was accelerated in vagotomized subjects compared with con-
trols during the saline infusion [time to peak plasma acetamin-
ophen: 67(36) vs. 152(21) min, P  0.0001]. GLP-1 had no
effect on the acetaminophen profile in vagotomized subjects
but powerfully suppressed and delayed gastric emptying in
control subjects [time to peak plasma acetaminophen: 75(38)
vs. 222(16) min, P  0.0001].
Glucose. Fasting PG differed between vagotomized subjects
and control subjects on the saline day (Table 4), but not on the
GLP-1 day (Fig. 4B). Peak PG concentrations were higher in
the vagotomized subjects after saline infusion [9.2(2.7) vs.
6.8(0.6), P  0.0100], and in this group, GLP-1 lowered
postprandial glucose levels at time 45–75 min (P  0.05),
whereas GLP-1 reduced postprandial PG levels below baseline
in control subjects at time 30–105 min (P 0.04). Total AUCs
were significantly reduced by GLP-1 in both groups (Table 4).
However, the vagotomized subjects had significantly higher total
AUCs than the controls during GLP-1 infusion. The reductions in
percent during GLP-1 infusion were similar [vagotomized:
15.7(10.6) vs. controls 13.0(6.9)%, P  NS].
GLP-1. Fasting GLP-1 levels were similar in the two groups
(Table 4 and Fig. 4C). However, peak meal-stimulated endog-
enous GLP-1 concentrations were higher in vagotomized sub-
jects relative to controls on the saline day [191(97) vs. 35(8)
pM, P  0.0011 (Fig. 4C)]. During GLP-1 infusions, peak
GLP-1 levels were also higher postprandially in the vagotomized
group [431(215) vs. 227(90) pM, P  0.0083]. In fact, the
meal-induced GLP-1 response on the saline day appeared to be
superimposed on the plateau generated by the infusion in the
vagotomized subjects. However, in the control subjects there may
be a slight feedback inhibition of endogenous GLP-1 secretion
during the GLP-1 infusion (Fig. 4C).
PP. There was no difference in fasting PP levels between the 2
experimental days in either group. However, fasting PP was
significantly lower in the vagotomized and higher in the control
group during the GLP-1 day (Table 2). The PP response to the
standard liquid mixed meal was completely unaffected by GLP-1
in the vagotomized group, whereas GLP-1 markedly reduced PP
responses in the control subjects (Table 2 and Fig. 4D).
Insulin and C-peptide. Fasting insulin and C-peptide levels
were similar in the two groups (Table 4 and Fig. 4, E and F).
The vagotomized subjects demonstrated a larger beta cell
response after the liquid meal with saline infusion compared
with the controls, as evaluated by the AUC for C-peptide
(Table 4) and two-way repeated-measures ANOVA, followed
by Bonferroni posttests for insulin (significant difference be-
tween the groups at time 60–90 min, P  0.01). However,
insulin secretion was unaffected by exogenous GLP-1 in va-
gotomized subjects, whereas it was suppressed in control
subjects (Table 4). Both groups displayed similar insulin re-
sistance, steady-state beta cell function, and insulin sensitivity
in the fasting state (Table 1).
Glucagon. The vagotomized subjects had significantly lower
fasting plasma glucagon levels on the saline day than the
controls, and there was a tendency toward the same on the
GLP-1 day (Table 4). The vagotomized subjects exhibited
hyperglucagonemia in response to the liquid meal during both
saline and GLP-1 infusions (Fig. 4G). In contrast to the
pronounced suppression of plasma glucagon in the control
subjects, exogenous GLP-1 had little effect in the vagotomized
group, when assessed during the early phase (AUC0–90 min) of
the meal [vagotomized subjects: 1,329(380) (saline) vs.
1,228(447) (GLP-1) pM, P  0.1184; control subjects:
933(279) (saline) vs. 618(315) (GLP-1) pM, P  0.0020].
DISCUSSION
Our findings indicate that vagotomy with pyloroplasty is
associated with 1) accelerated gastric emptying, 2) altered
glucose tolerance, 3) fivefold higher meal-stimulated GLP-1
secretion, 4) increased postprandial insulin and glucagon re-
sponses, and 5) an apparently diminished effect of exogenous
GLP-1 on meal-related insulin, glucagon, and PP secretion and
also on gastric emptying and ad libitum food intake.
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Fig. 2. Ad libitum food intake during saline infusion (bars without pattern) and
GLP-1 infusion (patterned bars) in vagotomized subjects and control subjects.
Data represent mean values and standard deviations from 20 vagotomized
subjects with pyloroplasty and 10 control subjects. *Significantly reduced food
intake in control subjects during GLP-1 infusion compared with saline (P 
0.0417).
Table 2. Palatability of the ad libitum meal with and
without GLP-1 infusion
Vagotomized Controls P
Visual appeal
Saline, cm 7.4 (2.5) 5.1 (2.0) 0.0221
GLP-1, cm 7.1 (2.3) 4.2 (1.5) 0.0017
P, saline vs. GLP-1 0.4722 0.1574
Smell
Saline, cm 7.4 (2.3) 5.8 (1.9) 0.0183
GLP-1, cm 7.5 (2.1) 5.4 (2.2) 0.0256
P, saline vs. GLP-1 0.6628 0.4897
Taste
Saline, cm 7.1 (2.4) 6.0 (2.1) 0.1993
GLP-1, cm 6.8 (2.1) 5.6 (2.2) 0.1719
P, saline vs. GLP-1 0.7092 0.6985
Aftertaste
Saline, cm 1.5 (1.5) 1.3 (1.4) 0.7723
GLP-1, cm 1.7 (2.3) 1.3 (0.7) 0.9324
P, saline vs. GLP-1 0.8507 0.9999
Overall palatability
Saline, cm 7.2 (2.2) 5.8 (2.0) 0.1115
GLP-1, cm 7.2 (3.0) 4.8 (1.9) 0.0111
P, saline vs. GLP-1 0.7531 0.2907
Data are mean values with SD in parentheses from 20 vagotomized subjects
with pyloroplasty and 10 control subjects. GLP-1, glucagon-like peptide-1.
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It could be a concern that the vagotomies were performed many
years earlier than the present study, particularly in the duodenal
ulcer patients. Therefore, the subjects underwent a chew-and-spit
sham feeding to evaluate their vagal integrity. Meal-induced PP
secretion is biphasic, where the early cephalic phase is vagally
mediated and the second prolonged phase is not wholly dependent
on vagal activity (61–63). The PP secretion immediately after the
sham feeding can, therefore, be used as a reliable test for vagal
integrity (4). The vagotomized subjects participating in this study
were characterized by a lack of the early cephalic PP response, in
contrast to the marked response in the control subjects, leading us
to believe that their vagotomies were still complete. We also
measured PG and GLP-1 before and after sham feeding, as a
control for anything being swallowed, and noted a small rise in
PG values from baseline at all time points in both groups. It
cannot, therefore, be fully excluded that small amounts of food,
drink, or saliva were swallowed during sham feeding despite our
efforts. However, the rise in PG was very small and observed in
both groups, so any nutrient-dependent increase in PP secretion
would also be small and equal in both groups. Moreover, it is well
established that GLP-1 is secreted in response to nutrients in the
intestine (31) and GLP-1 levels were unchanged during sham
feeding, supporting the assumption of absence of nutrient-depen-
dent activation of PP secretion.
No differences were seen in appetite sensations in either
group of subjects when comparing saline and GLP-1 infusions.
This was unexpected, since GLP-1 repeatedly has been shown
to inhibit sensations of appetite (19, 24, 49). VAS recordings of
appetite are not particularly sensitive, but according to Flint et
al. (20) our number of subjects should have been sufficient to
detect clinically relevant differences. However, the technique
has not been validated in an elderly age group, as studied here.
Moreover, Gutzwiller and colleagues (26) previously reported
that only high doses of GLP-1 infusion (1.5 pmol·kg1·min1)
resulted in a statistically significant difference in the sensation
of (only) hunger, whereas lower doses (0.375, 0.75, and 1.5
pmol·kg1·min1) still inhibited food intake. In our study, we
only administered 1.2 pmol·kg1·min1 of GLP-1, possibly
explaining the missing effect of GLP-1 on appetite. Neverthe-
less, GLP-1 had no effect ad libitum food intake in the
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Fig. 3. Subjective appetite ratings of appetite (A), hunger (B), prospective food intake (C), satiety (D), fullness (E), thirst (F), well-being (G), and nausea (H)
scores from visual analog scales before and after a mixed meal with concomitant saline infusion (open symbols) or GLP-1 infusion (solid symbols) in
vagotomized subjects (circles) and control subjects (squares). Infusions were started at 0 min and lasted throughout the study. The standardized liquid mixed meal
was served at 30 min and was consumed during 10 min. Data are mean values and standard deviation from 20 vagotomized subjects with pyloroplasty and 10
control subjects.
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vagotomized subjects, whereas there was a significant reduc-
tion in the control group. In accordance with this, the effect of
intraperitoneal GLP-1 on food intake in rodents was lost after
both total subdiaphragmatic vagotomy (1) and selective vagal
deafferentation (59). Similarly, vagal sensory ablation using
capsaicin treatment in mice abolished the inhibitory effect of
the GLP-1 agonist exendin-4 (65). All of these observations
support a role for sensory afferents in mediating effect of
GLP-1 on food intake. There are also other possible mecha-
nisms of action for GLP-1, especially with respect to the
effects on appetite, food intake, and the adverse reaction
nausea, which can be triggered by large doses of GLP-1 (57).
It has been demonstrated in rodents that there are GLP-1Rs in
the subfornical organ and the area postrema accessible to
peripherally circulating GLP-1 (51). In addition, studies in rats
have clearly demonstrated that inhibition of food intake can be
elicited by intravenous administration of GLP-1 and this effect
is not affected by subdiaphragmatic deafferentation (59). The
effect of vagotomy observed here, however, supports a role for
vagal mediation of the effect of GLP-1 on food intake in
humans.
Nauck et al. (45) showed that the effects of GLP-1 on gastric
emptying as estimated by using a two-meal protocol shows
rapid tachyphylaxis in humans, and, since there was also a
marked reduction in PP levels (used as a marker for vagal
activity) after the first but not the second meal, they suggested
that the tachyphylaxis happened at the level of vagal activation.
This might suggest that other effects of GLP-1 may also be
subject to rapid tachyphylaxis, perhaps at the level of vagal
activation. However, GLP-1-induced improvements in meta-
bolic control and body weight are maintained during long-term
treatment with both GLP-1 and long-acting GLP-1 receptor
analogs (32, 56, 72), indicating that, except for inhibition of
gastric emptying, the effects of GLP-1 do not show tachyphy-
laxis. Moreover, other studies involving several hours of
GLP-1 infusion to concentrations comparable to those used in
this study (3, 19, 25, 26) have demonstrated maintained reduc-
tion of food intake at a subsequent ad libitum meal. Another
explanation for the lack of effect in the vagotomized group
might be the age of the participants. A study by Gregersen et
al. (22) indicated decreasing postprandial hunger and desire to
eat with increasing age. However, our control subjects were
carefully matched for age. To obtain an independent measure
of vagal activity, we measured PP responses to the standard-
ized liquid mixed meal and found that the PP responses were
identical during the two experimental conditions in the vagot-
omized group, indicating that GLP-1 did not affect PP secre-
tion in this group. In contrast, the PP response was dramatically
reduced during GLP-1 infusion in the control subjects. Al-
though the postprandial PP responses may not be entirely
vagally driven (although clearly dependent on cholinergic
muscarinic mechanisms) as discussed above and may be re-
lated to differences in gastric emptying, as also shown in
patients with Type 1 diabetes (16, 17), it remains highly likely
that GLP-1 reduces the efferent, vagally mediated signals for
PP secretion (61). The PP data, therefore, strongly support the
concept that GLP-1 regulation of postprandial PP secretion and
appetite involves the vagus nerve.
Accelerated gastric emptying, particularly for liquids, is a
known consequence of the pyloroplasty performed in connec-
tion with vagotomy (37, 53) and, as expected, gastric empty-
ing, evaluated by use of acetaminophen, was faster in the
vagotomized subjects than in the controls. Gastric emptying
was not affected by exogenous GLP-1 in these subjects. This
would be consistent with a study by Imeryüz et al. (35) in rats,
in which capsaicin-induced block of vagal sensory afferents
abolished the inhibitory effect of GLP-1 on gastric emptying
Table 3. Appetite and wellness sensations before (baseline)
and after a mixed meal (area under curve) with and without
GLP-1 infusion
Vagotomized Controls P
Appetite score
BaselineSaline, cm 5.0 (2.0) 5.0 (1.2) 0.7373
BaselineGLP-1, cm 5.0 (2.1) 5.0 (1.9) 0.4858
P, saline vs. GLP-1 0.9101 0.5237
tAUCSaline, cmmin 1,174 (448) 1,215 (363) 0.0189
tAUCGLP-1, cmmin 1,172 (394) 1,213 (349) 0.0097
P, saline vs. GLP-1 0.6548 0.6607
Hunger
BaselineSaline, cm 3.6 (2.3) 2.7 (2.2) 0.8946
BaselineGLP-1, cm 3.5 (2.9) 4.0 (2.4) 0.6485
P, saline vs. GLP-1 0.7744 0.0669
tAUCSaline, cmmin 822 (473) 1,094 (422) 0.1348
tAUCGLP-1, cmmin 771 (402) 1,109 (467) 0.0529
P, saline vs. GLP-1 0.4982 0.8540
Prospective food intake
BaselineSaline, cm 4.0 (2.1) 5.3 (1.7) 0.0940
BaselineGLP-1, cm 4.2 (2.3) 4.8 (2.1) 0.4613
P, saline vs. GLP-1 0.7058 0.5653
tAUCSaline, cmmin 838 (472) 1,307 (444) 0.0141
tAUCGLP-1, cmmin 851 (436) 1,247 (409) 0.0235
P, saline vs. GLP-1 0.8430 0.3995
Satiety
BaselineSaline, cm 4.7 (2.8) 4.2 (1.3) 0.8503
BaselineGLP-1, cm 5.0 (2.6) 3.8 (2.0) 0.9199
P, saline vs. GLP-1 0.4691 0.3594
tAUCSaline, cmmin 1,359 (475) 968 (395) 0.0334
tAUCGLP-1, cmmin 1,400 (438) 933 (354) 0.0069
P, saline vs. GLP-1 0.3296 0.4810
Fullness
BaselineSaline, cm 3.5 (2.6) 3.4 (1.7) 0.9395
BaselineGLP-1, cm 3.4 (2.4) 3.5 (2.3) 0.9572
P, saline vs. GLP-1 0.8798 0.9105
tAUCSaline, cmmin 1,345 (498) 847 (300) 0.0072
tAUCGLP-1, cmmin 1,356 (452) 917 (327) 0.0110
P, saline vs. GLP-1 0.8176 0.0889
Thirst
BaselineSaline, cm 5.3 (2.7) 5.0 (2.6) 0.7359
BaselineGLP-1, cm 4.9 (2.6) 5.5 (2.4) 0.5412
P, saline vs. GLP-1 0.5263 0.5578
tAUCSaline, cmmin 1,247 (670) 1,336 (500) 0.7137
tAUCGLP-1, cmmin 1,251 (605) 1,286 (549) 0.8779
P, saline vs. GLP-1 0.9397 0.5497
Well-being
BaselineSaline, cm 7.5 (2.5) 8.1 (1.4) 0.8882
BaselineGLP-1, cm 8.4 (1.2) 8.1 (1.4) 0.4404
P, saline vs. GLP-1 0.0888 0.7500
tAUCSaline, cmmin 1,843 (523) 1,942 (329) 0.6031
tAUCGLP-1, cmmin 1,871 (474) 1,940 (289) 0.7207
P, saline vs. GLP-1 0.6463 0.7695
Nausea
BaselineSaline, cm 0.9 (1.3) 0.4 (0.4) 0.8503
BaselineGLP-1, cm 0.9 (1.1) 0.9 (1.6) 0.9199
P, saline vs. GLP-1 0.9669 0.3135
tAUCSaline, cmmin 271 (344) 183 (150) 0.8883
tAUCGLP-1, cmmin 344 (348) 249 (307) 0.4621
P, saline vs. GLP-1 0.0663 0.8457
Data are mean values with SD in parentheses from 20 vagotomized subjects
with pyloroplasty and 10 control subjects. tAUC, total area under the curve.
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(35) and the lack of effect of GLP-1 on gastric volume in
diabetic patients with vagal neuropathy (14), and suggests that
GLP-1 inhibits gastric tone through a mechanism involving the
vagus nerve. However, the lack of effect of GLP-1 on gastric
emptying observed in the vagotomized subjects could also be
a consequence of the pyloroplasty. The mechanism whereby
GLP-1 inhibits gastric emptying may involve both reduced
antral motility (70) and closure of the pylorus (60). Although
the reduction of antral motility probably involves inhibition of
vagal outflow (70), the closure of the pylorus is likely to be
impeded by the pyloroplasty, and it is therefore plausible that
latter is responsible for part of the loss of the GLP-1 effect in
our patients. The lack of effect after vagotomy is consistent
with the concept that the effect of GLP-1 is vagally mediated.
The accelerated gastric emptying observed in the vagoto-
mized subjects leads to rapid delivery of nutrients to the small
intestine, a pattern also seen in gastric bypass-operated subjects
(36). This undoubtedly influences many of the parameters in
this study e.g., GLP-1 secretion, PG levels, and insulin re-
sponses, and must be taken into account when evaluating the
results. Nevertheless, the participants serve as their own con-
trol, so, although it may be difficult to compare vagotomized to
control subjects (because of the difference in gastric emptying
and therefore delivery of nutrients to the small intestine),
comparison of the effect of saline and GLP-1 infusions within
the groups is still justified.
In agreement with the accelerated gastric emptying, PG
increased rapidly after the standardized liquid mixed meal in
the vagotomized subjects, with peak PG concentrations being
much higher than in the control subjects. Despite this, the
vagotomized subjects were effective at eliminating glucose
from the plasma compartment, with levels returning to baseline
after 2 h. Therefore, in accordance with previous observations
(33, 34), vagotomy with pyloroplasty is not associated with
impaired glucose tolerance, but rather an altered glucose ho-
meostasis. However, despite the very high plasma levels of
GLP-1 in the vagotomized subjects after infusion, the frac-
tional lowering of postprandial PG was affected similarly in the
two groups. It is unlikely that this is a consequence of changes
in gastric emptying, insulin, or glucagon secretion, since
GLP-1 had little effect on these parameters in the vagotomized
subjects. A study by Corssmit et al. (9) indicated that truncal
vagotomy does not affect the fasting (16–22 h) postabsorptive
glucose metabolism or the levels of certain regulatory hor-
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Fig. 4. Time courses of plasma acetaminophen (A), plasma glucose (B), total GLP-1 (C), pancreatic polypeptide (D), insulin (E), C-peptide (F), and glucagon
(G) before and after a mixed meal (with acetaminophen) with saline infusion (open symbols) and GLP-1 infusion (solid symbols) in vagotomized subjects
(circles) and control subjects (squares). Infusions were started at 0 min and lasted throughout the meal test. The standardized liquid mixed meal was served at
30 min and was consumed during 10 min. Data represent mean values and standard deviations from 20 vagotomized subjects with pyloroplasty and 10 control
subjects.
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mones. It is also likely that the parasympathic nerves are less
important for the regulation of basal glucose metabolism, as
also shown by Boyle et al. (7) using atropine in healthy
participants. However, these observations apply to the fasted
state only. A study by Henderson et al. (29) showed reduced
insulin secretion after atropine administration after oral but not
intravenous glucose in humans (probably unrelated to changes
in gastric emptying, since the rising phase of the glucose
profiles with and without atropine were identical), indicating
that reduction of insulin secretion induced by atropine does not
result from inhibition of muscarinic receptors on the beta cells,
but from blockade of a signal initiated in the gastrointestinal
tract. Similarly, other studies in vagotomized subjects found
reduced insulin secretion during oral but not intravenous glu-
cose loads compared with unoperated ulcer patient (33, 34).
These data support a role for the intestine and parasympathetic
nerves in the postprandial glucose metabolism. Our vagoto-
mized subjects had significantly higher (compared with con-
trols) postprandial insulin secretion during the saline infusion,
as evident by both insulin (ANOVA) and C-peptide (total
AUC) responses, consistent with the elevated PG levels and
increased GLP-1 secretion. Although this may be due to the
accelerated gastric emptying and the rapid delivery of nutrients
to the small intestine (38, 40), it is noteworthy that exogenous
GLP-1 did not affect or further enhance insulin secretion in
these subjects. This was surprising given the high GLP-1 levels
in the vagotomized subjects after the GLP-1 infusion and the
failure of GLP-1 to inhibit gastric emptying, both of which
would be expected to further enhance insulin secretion (31, 47,
50). Thus, in studies in healthy subjects, where similar levels of
glucose and GLP-1 were mimicked by intravenous infusions,
insulin levels were greatly elevated, resulting in pronounced
reactive hypoglycemia (66). Together, these findings are con-
sistent with an impairment of the insulinotropic effect of
GLP-1 after vagotomy, as also shown in rodents (2, 5, 35). On
the other hand, the lower glucose levels during the GLP-1
infusion are likely to contribute to the missing response to the
high GLP-1 levels under these conditions. Further studies are
therefore needed to unravel these relationships. In contrast, in
the control subjects, insulin secretion was suppressed during
exogenous GLP-1 infusion, presumably because of the inhibi-
tion of gastric emptying by GLP-1, as previously shown (47).
Vagotomy with pyloroplasty was also associated with post-
prandial hyperglucagonemia during saline infusion as well as
during GLP-1 infusion, with exogenous GLP-1 failing to
suppress glucagon levels, particularly in the early phase of the
meal. This is all the more surprising since the elevated GLP-1
levels in the vagotomized subjects would be expected to cause
greater suppression (50). It is therefore possible that GLP-1’s
glucagonostatic effects may also be impaired after vagotomy.
However, the mechanism, which could include an absent vagal
signaling, reduced alpha cell and/or beta cell sensitivity, and/or
gastrointestinal factors, remains to be clarified.
GLP-1 levels were higher in the vagotomized group than in the
controls after the standardized liquid mixed meal on both days.
Based on studies in rodents, it has been claimed that the vagus
nerve plays an important role in GLP-1 secretion (58). However,
vagotomy and vagus stimulation in pigs did not affect secretion of
either GLP-1 or the other incretin hormone, glucose-dependent
insulinotropic polypeptide (GIP) (6). Furthermore, in another
detailed study in pigs, there were no changes in GLP-1 or GLP-2
and only weak effects on GIP secretion after electrical stimulation
of the vagal trunks at the level of the diaphragm (28) despite clear
effects on the release of vagal neurotransmitters. In the vagoto-
mized subjects the meal-induced GLP-1 response on the saline
day appeared to be superimposed on the plateau generated by
the infusion, indicating that the exogenous GLP-1 infusion did
not affect endogenous meal-related GLP-1 secretion in these
subjects. This was unexpected since a feedback inhibition of
GLP-1 secretion has previously been demonstrated in humans
during GLP-1 infusion (21) and during DPP-4 inhibition in
humans (18) and dogs (12). The control subjects probably
responded with feedback inhibition of endogenous GLP-1
secretion during the GLP-1 infusion (as evidenced by a lack of
rise above the plateau during the meal), as expected. This raises
the intriguing possibility that the mechanism of the feedback
inhibition involves vagal pathways, but elucidation of this will
require further experiments.
Table 4. Fasting plasma concentrations and postprandial
responses of glucose, GLP-1, insulin, and glucagon with
and without GLP-1 infusion
Vagotomized Controls P
Glucose
BaselineSaline, mM 5.8 (0.9) 5.1 (0.5) 0.0301
BaselineGLP-1, mM 5.8 (0.8) 5.4 (0.3) 0.2345
P, saline vs. GLP-1 0.4806 0.1093
tAUCSaline, mMmin 1,508 (216) 1,381 (78) 0.0847
tAUCGLP-1, mMmin 1,303 (145) 1,212 (73) 0.0237
P, saline vs. GLP-1 0.0001 0.0005
Total GLP-1
BaselineSaline, pM 13.6 (6.0) 14.2 (5.8) 0.7868
BaselineGLP-1, pM 13.1 (11.7) 9.8 (3.5) 0.7695
P, Saline vs. GLP-1 0.3370 0.1251
tAUCSaline, nMmin 14.3 (5.1) 5.9 (1.3) 0.0001
tAUCGLP-1, nMmin 56.2 (12.9) 41.6 (4.6) 0.0018
P, saline vs. GLP-1 0.0001 0.0001
PP
BaselineSaline, pM 29 (35) 14 (11) 0.1391
BaselineGLP-1, pM 18 (17) 23 (19) 0.6570
P, saline vs. GLP-1 0.0022 0.0300
tAUCSaline, nMmin 16.6 (12.4) 11.5 (7.6) 0.2418
tAUCGLP-1, nMmin 17.5 (11.8) 6.8 (4.5) 0.038
P, saline vs. GLP-1 0.3118 0.0019
Insulin
BaselineSaline, pM 68 (76) 41 (23) 0.3410
BaselineGLP-1, pM 67 (70) 44 (20) 0.6110
P, saline vs. GLP-1 0.6150 0.3945
tAUCSaline, nMmin 67.3 (59.5) 32,721 (14.2) 0.0884
tAUCGLP-1, nMmin 75.0 (91.5) 22.2 (10.8) 0.0054
P, saline vs. GLP-1 0.8408 0.0116
C-peptide
BaselineSaline, pM 576 (285) 409 (162) 0.0502
BaselineGLP-1, pM 558 (255) 433 (166) 0.1389
P, saline vs. GLP-1 0.4524 0.3578
tAUCSaline, nM240 min 359.3 (181.3) 227.5 (59.1) 0.0343
tAUCGLP-1, nM240 min 368.7 (220.4) 176.9 (54.0) 0.0013
P, saline vs. GLP-1 0.9604 0.0098
Glucagon
BaselineSaline, pM 6.8 (2.0) 9.3 (3.2) 0.0297
BaselineGLP-1, pM 6.7 (2.3) 9.3 (4.9) 0.0717
P, Saline vs. GLP-1 0.8622 1.000
tAUCSaline, pM240 min 3,703 (957) 2,203 (577) 0.0001
tAUCGLP-1, pM240 min 3,264 (870) 1,486 (542) 0.0001
P, saline vs. GLP-1 0.0205 0.0020
Data are mean values with SD in parentheses from 20 vagotomized subjects
with pyleroplasty and 10 control subjects. PP, pancreatic polypeptide.
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In conclusion, in vagotomized subjects with pyloroplasty the
effect of exogenous GLP-1 on food intake and gastric empty-
ing is diminished. Furthermore, vagotomized subjects with
pyloroplasty exhibit altered glucose tolerance and approxi-
mately fivefold higher endogenous GLP-1 levels, presumably
caused by accelerated gastric emptying. Additionally, vagot-
omy is associated with reduced insulinotropic and glucagono-
static effects of exogenous GLP-1. Therefore, the vagus prob-
ably plays an important role in mediating the physiological and
pharmacological effects of GLP-1. However, further studies
aiming at eliminating the effects of the associated pyloroplasty
are needed to define more clearly the contributions of vagal
transmission to the effects of GLP-1.
ACKNOWLEDGMENTS
We thank all participants for spending their time on this project and we are
most grateful for expert technical assistance from Jytte Purtoft, Nina Kjeldsen,
Sofie P. Olesen, and Lene Albæk.
GRANTS
The study was supported by a grant from The Danish Diabetes Association
and the Danish Medical Research Council.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
A.P., A.W., T.V., F.K.K., and J.J.H. conception and design of research;
A.P. and S.V. performed experiments; A.P., S.V., C.F.D., T.V., F.K.K., and
J.J.H. interpreted results of experiments; A.P. prepared figures; A.P. drafted
manuscript; A.P., S.V., C.F.D., B.H., A.W., L.B.S., S.M., C.H., T.V., F.K.K.,
and J.J.H. edited and revised manuscript; A.P., S.V., C.F.D., B.H., A.W.,
L.B.S., S.M., C.H., T.V., F.K.K., and J.J.H. approved final version of manu-
script; B.H. analyzed data.
REFERENCES
1. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson
JRC, Ghatei MA, Bloom SR. The inhibitory effects of peripheral admin-
istration of peptide YY(3-36) and glucagon-like peptide-1 on food intake
are attenuated by ablation of the vagal-brainstem-hypothalamic pathway.
Brain Res 1044: 127–131, 2005.
2. Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like
peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 286: R269–
R272, 2004.
3. Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ. Do the actions of
glucagon-like peptide-1 on gastric emptying, appetite, and food intake
involve release of amylin in humans? J Clin Endocrinol Metab 95:
2367–2375, 2010.
4. Balaji NS, Crookes PF, Banki F, Hagen JA, Ardill JE, DeMeester TR.
A safe and noninvasive test for vagal integrity revisited. Arch Surg 137:
954–958; discussion 958–959, 2002.
5. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin
response to glucose via neuronal mechanisms. Am J Physiol Regul Integr
Comp Physiol 279: R1449–R1454, 2000.
6. Blat S, Guérin S, Chauvin A, Sève B, Morgan L, Cuber JC, Malbert
CH. The vagus is inhibitory of the late postprandial insulin secretion in
conscious pigs. Auton Neurosci 101: 68–77, 2002.
7. Boyle PJ, Liggett SB, Shah SD, Cryer PE. Direct muscarinic cholinergic
inhibition of hepatic glucose production in humans. J Clin Invest 82:
445–449, 1988.
8. Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst
JJ, Hellström PM. Receptor-mediated activation of gastric vagal affer-
ents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 21:
978-e78, 2009.
9. Corssmit EP, Van Lanschot JJ, Romijn JA, Endert E, Sauerwein HP.
Truncal vagotomy does not affect postabsorptive glucose metabolism in
humans. J Appl Physiol 79: 97–101, 1995.
10. Deacon CF, Johnsen AH, Holst JJ. Human colon produces fully pro-
cessed glucagon-like peptide-1 (7-36) amide. FEBS Lett 372: 269–272,
1995.
11. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like
peptide 1 undergoes differential tissue-specific metabolism in the anesthe-
tized pig. Am J Physiol Endocrinol Metab 271: E458–E464, 1996.
12. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of
active incretin hormones by inhibition of dipeptidyl peptidase IV sup-
presses meal-induced incretin secretion in dogs. J Endocrinol 172: 355–
362, 2002.
13. Deane AM, Nguyen NQ, Stevens JE, Fraser RJL, Holloway RH,
Besanko LK, Burgstad C, Jones KL, Chapman MJ, Rayner CK,
Horowitz M. Endogenous glucagon-like peptide-1 slows gastric emptying
in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol
Metab 95: 215–221, 2010.
14. Delgado-Aros S, Vella A, Camilleri M, Low PA, Burton DD, Thom-
forde GM, Stephens D. Effects of glucagon-like peptide-1 and feeding on
gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neu-
rogastroenterol Motil 15: 435–443, 2003.
15. Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Jacobsen
SH, Clausen TR, Worm D, Hartmann B, Rehfeld JF, Damgaard M,
Madsen JL, Madsbad S, Holst JJ, Hansen DL. Gut hormones, early
dumping and resting energy expenditure in patients with good and poor
weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond)
(February 19, 2013). doi: 10.1038/ijo.2013.15.
16. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP,
Zabel P, McDonald TJ. Glucagon-like peptide I reduces postprandial
glycemic excursions in IDDM. Diabetes 44: 626–630, 1995.
17. Dupré J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal
glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 89:
3469–3473, 2004.
18. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D,
Nauck MA. The dipeptidyl peptidase 4 inhibitor vildagliptin does not
accentuate glibenclamide-induced hypoglycemia but reduces glucose-
induced glucagon-like peptide 1 and gastric inhibitory polypeptide secre-
tion. J Clin Endocrinol Metab 92: 4165–4171, 2007.
19. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes
satiety and suppresses energy intake in humans. J Clin Invest 101:
515–520, 1998.
20. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and
validity of visual analogue scales in assessment of appetite sensations in
single test meal studies. Int J Obes Relat Metab Disord 24: 38–48, 2000.
21. Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A. The effect of
physiological levels of glucagon-like peptide-1 on appetite, gastric emp-
tying, energy and substrate metabolism in obesity. Int J Obes Relat Metab
Disord 25: 781–792, 2001.
22. Gregersen NT, Møller BK, Raben A, Kristensen ST, Holm L, Flint A,
Astrup A. Determinants of appetite ratings: the role of age, gender, BMI,
physical activity, smoking habits, and diet/weight concern. Food Nutr Res
55, 2011. doi: 10.3402/fnr.v55i0.7028. Epub 2011 Aug 11.
23. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone
secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch
435: 583–594, 1998.
24. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J,
Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food
intake in patients with diabetes mellitus type 2. Am J Physiol Regul Integr
Comp Physiol 276: R1541–R1544, 1999.
25. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J,
Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food
intake in patients with diabetes mellitus type 2. Am J Physiol Regul Integr
Comp Physiol 276: R1541–R1544, 1999.
26. Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin
D, Winterhalder R, Conen D, Beglinger C. Glucagon-like peptide-1: a
potent regulator of food intake in humans. Gut 44: 81–86, 1999.
27. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-
(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by
dipeptidyl peptidase IV in the capillaries supplying the L cells of the
porcine intestine. Endocrinology 140: 5356–5363, 1999.
28. Hansen L, Lampert S, Mineo H, Holst JJ. Neural regulation of gluca-
gon-like peptide-1 secretion in pigs. Am J Physiol Endocrinol Metab 287:
E939–E947, 2004.
29. Henderson JR, Jefferys DB, Jones RH, Stanley D. The effect of
atropine on the insulin release caused by oral and intravenous glucose in
human subjects. Acta Endocrinol 83: 772–780, 1976.
G1126 IMPORTANCE OF THE VAGUS NERVE FOR GLP-1 EFFECTS
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00035.2013 • www.ajpgi.org
 by 10.220.33.3 on February 13, 2017
http://ajpgi.physiology.org/
D
ow
nloaded from
 
30. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87:
1409–1439, 2007.
31. Holst. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling
nutritional abundance, with an unusual therapeutic potential. Trends En-
docrinol Metab 10: 229–235, 1999.
32. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy
of lixisenatide for the management of type 2 diabetes. Adv Ther 30:
81–101, 2013.
33. Humphrey CS, Dykes JR, Johnston D. Effects of truncal, selective, and
highly selective vagotomy on glucose tolerance and insulin secretion in
patients with duodenal ulcer. Part II-Comparison of response to oral and
intravenous glucose. Br Med J 2: 114–116, 1975.
34. Humphrey CS, Dykes JR, Johnston D. Effects of truncal, selective, and
highly selective vagotomy on glucose tolerance and insulin secretion in
patients with duodenal ulcer. Part I-Effect of vagotomy on response to oral
glucose. Br Med J 2: 112–114, 1975.
35. Imeryüz N, Yeg˘en BC, Bozkurt A, Cos¸kun T, Villanueva-Peñacarrillo
ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via
vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest
Liver Physiol 273: G920–G927, 1997.
36. Jorgensen NB, Jacobsen SH, Dirksen C, Bojsen-Moller KN, Naver L,
Hvolris L, Clausen TR, Wulff BS, Worm D, Hansen DL, Madsbad S,
Holst JJ. Acute and long-term effects of Roux-en-Y gastric bypass on
glucose metabolism in subjects with Type 2 diabetes and normal glucose
tolerance. Am J Physiol Endocrinol Metab 303: (1) E122–E131, 2012.
37. Kronborg O, Madsen P. Gastric emptying rate and acid secretion after
truncal vagotomy and pyloroplasty for duodenal ulceration. Scand J
Gastroenterol 7: 515–518, 1972.
38. Ma J, Pilichiewicz AN, Feinle-Bisset C, Wishart JM, Jones KL,
Horowitz M, Rayner CK. Effects of variations in duodenal glucose load
on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet
Med 29: 604–608, 2012.
39. Medhus AW, Lofthus CM, Bredesen J, Husebye E. Gastric emptying:
the validity of the paracetamol absorption test adjusted for individual
pharmacokinetics. Neurogastroenterol Motil 13: 179–185, 2001.
40. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antago-
nizes the deceleration of gastric emptying by glucagon-like peptide 1 and
unmasks its insulinotropic effect in healthy subjects. Diabetes 54: 2212–
2218, 2005.
41. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydro-
lyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide,
peptide histidine methionine and is responsible for their degradation in
human serum. Eur J Biochem 214: 829–835, 1993.
42. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-gluca-
gon and glucagon-like peptide-1 receptor messenger RNAs in the rat
central nervous system. J Comp Neurol 403: 261–280, 1999.
43. Miceli JN, Aravind MK, Cohen SN, Done AK. Simultaneous measure-
ments of acetaminophen and salicylate in plasma by liquid chromatogra-
phy. Clin Chem 25: 1002–1004, 1979.
44. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K,
Nakano S, Kigoshi T, Nakayama K, Uchida K. Receptor gene expression
of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypep-
tide, in rat nodose ganglion cells. Auton Neurosci 110: 36–43, 2004.
45. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of
the glucagon-like peptide 1-induced deceleration of gastric emptying in
humans. Diabetes 60: 1561–1565, 2011.
46. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.
Normalization of fasting hyperglycaemia by exogenous glucagon-like
peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Diabetologia 36: 741–744, 1993.
47. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R,
Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying
outweighs its insulinotropic effects in healthy humans. Am J Physiol
Endocrinol Metab 273: E981–E988, 1997.
48. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Niijima A. The
hepatic vagal nerve is receptive to incretin hormone glucagon-like pep-
tide-1, but not to glucose-dependent insulinotropic polypeptide, in the
portal vein. J Auton Nerv Syst 61: 149–154, 1996.
49. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ,
Rössner S, Hellström PM. Energy intake and appetite are suppressed by
glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab
Disord 23: 304–311, 1999.
50. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like
peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig
pancreas, antrum, and nonantral stomach. Endocrinology 123: 2009–
2013, 1988.
51. Orskov C, Poulsen SS, Møller M, Holst JJ. Glucagon-like peptide I
receptors in the subfornical organ and the area postrema are accessible to
circulating glucagon-like peptide I. Diabetes 45: 832–835, 1996.
52. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and
plasma concentrations of amidated and glycine-extended glucagon-like
peptide I in humans. Diabetes 43: 535–539, 1994.
53. Parr NJ, Grime S, Critchley M, Baxter JN, Mackie CR. Mechanisms
governing the biphasic pattern of gastric emptying after truncal vagotomy
and pyloroplasty. Gut 29: 1253–1257, 1988.
54. Pennathur A, Awais O, Luketich JD. Technique of minimally invasive
Ivor Lewis esophagectomy. Ann Thorac Surg 89: S2159–S2162, 2010.
55. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase
24.11 and dipeptidyl peptidase IV are both mediators of the degradation of
glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48: 1882–
1890, 2005.
56. Ponzani P. Long-term effectiveness and safety of liraglutide in clinical
practice. Minerva Endocrinol 38: 103–112, 2013.
57. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulino-
tropic, and glucagonostatic properties of GLP-1 [7-36 amide] after sub-
cutaneous injection in healthy volunteers. Dose-response-relationships.
Diabetologia 38: 720–725, 1995.
58. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal
nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140:
1687–1694, 1999.
59. Rüttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W.
Intrameal hepatic portal and intraperitoneal infusions of glucagon-like
peptide-1 reduce spontaneous meal size in the rat via different mecha-
nisms. Endocrinology 150: 1174–1181, 2009.
60. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ,
Göke B. Endogenous glucagon-like peptide 1 controls endocrine pancre-
atic secretion and antro-pyloro-duodenal motility in humans. Gut 55:
243–251, 2006.
61. Schwartz TW, Holst JJ, Fahrenkrug J, Jensen SL, Nielsen OV,
Rehfeld JF, De Muckadell OB, Stadil F. Vagal, cholinergic regulation of
pancreatic polypeptide secretion. J Clin Invest 61: 781–789, 1978.
62. Schwartz TW, Rehfeld JF, Stadil F, Larson LI, Chance RE, Moon N.
Pancreatic-polypeptide response to food in duodenal-ulcer patients before
and after vagotomy. Lancet 1: 1102–1105, 1976.
63. Schwartz TW, Stenquist B, Olbe L. Cephalic phase of pancreatic-
polypeptide secretion studied by sham feeding in man. Scand J Gastro-
enterol 14: 313–320, 1979.
64. Sloth B, Due A, Larsen TM, Holst JJ, Heding A, Astrup A. The effect
of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite
and glucose metabolism during a 6-month weight maintenance period. Br
J Nutr 101: 1846–1858, 2009.
65. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exen-
din-4 and peptide YY(3-36) synergistically reduce food intake through dif-
ferent mechanisms in mice. Endocrinology 146: 3748–3756, 2005.
66. Toft-Nielsen M, Madsbad S, Holst JJ. Exaggerated secretion of gluca-
gon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabe-
tologia 41: 1180–1186, 1998.
67. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD,
Ellis KS, Woods SC, Seeley RJ, Herman JP, D’Alessio DA. Glucagon-
like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal
vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
Endocrinology 148: 4965–4973, 2007.
68. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagonlike peptide
I (7-37) actions on endocrine pancreas. Diabetes 38: 338–342, 1989.
69. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen
J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric
and pancreatic functions in man. Dig Dis Sci 38: 665–673, 1993.
70. Wettergren A, Wøjdemann M, Holst JJ. Glucagon-like peptide-1 in-
hibits gastropancreatic function by inhibiting central parasympathetic
outflow. Am J Physiol Gastrointest Liver Physiol 275: G984–G992, 1998.
71. Willems M, Quartero AO, Numans ME. How useful is paracetamol
absorption as a marker of gastric emptying? A systematic literature study.
Dig Dis Sci 46: 2256–2262, 2001.
72. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course
of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and
beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:
824–830, 2002.
G1127IMPORTANCE OF THE VAGUS NERVE FOR GLP-1 EFFECTS
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00035.2013 • www.ajpgi.org
 by 10.220.33.3 on February 13, 2017
http://ajpgi.physiology.org/
D
ow
nloaded from
 
